Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Microbicide trial results a turning point for HIV prevention, says team testing same gel

20.07.2010
CAPRISA 004 finds tenofovir gel used before and after sex reduced HIV by 39 percent in women; daily gel use being tested in VOICE

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

CAPRISA 004 involved 889 women from Durban and a nearby rural community in South Africa, where women are at especially high risk of acquiring HIV through sexual intercourse. Women were randomly assigned to one of two study groups ¡V tenofovir gel or placebo gel with no active ingredient ¡Vand instructed to use the study product in a regimen timed before and after sex. At the end of the study, there were 39 percent fewer HIV infections among women who used tenofovir gel before and after sex than among those who used the placebo gel. The study was conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA).

"This study has established proof of concept that a vaginal microbicide containing an ARV can protect women from HIV. This is an incredibly important achievement for which the CAPRISA team is to be congratulated. For all of us in the HIV prevention field, this result has shown that it may be possible to leverage this initial success using a single ARV at the time of sex into more potent approaches that could be 50, 60 or even 70 percent effective for prevention of HIV. The results of this study have reinvigorated the field," commented Sharon Hillier, Ph.D., professor and vice chair for faculty affairs, and director of reproductive infectious disease research in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine, and principal investigator of the Microbicide Trials Network (MTN).

The MTN currently is conducting another study called VOICE ¡V Vaginal and Oral Interventions to Control the Epidemic ¡V that will provide evidence about the safety and efficacy of tenofovir gel used daily, regardless of when participants have sex. VOICE, sometimes referred to as MTN-003, also is evaluating another promising approach called oral pre-exposure prophylaxis (PrEP), which involves daily use of an ARV tablet (tenofovir or Truvada„µ). VOICE is the first HIV prevention trial testing two different approaches in the same study and the first effectiveness trial of a microbicide in which women use the gel every day instead of only around the time of sex. The study plans to enroll about 5,000 women at sites in South Africa, Uganda, Zimbabwe and Malawi. Nearly 1,000 women have been enrolled so far.

Tenofovir gel and the tablets being tested in VOICE and other PrEP trials incorporate some of the same ARV medicines used successfully for treatment of HIV. The hope is that they will also be safe and effective for HIV prevention.

"CAPRISA's contribution to our understanding of how topically applied ARVs could prevent HIV is extraordinary. The results of this study bode well for the future of microbicide research and for investigation of ARV-based prevention for men and women worldwide. And as the first completed effectiveness study involving ARVs for prevention, CAPRISA 004 raises the bar for VOICE. I would argue that VOICE is more relevant than ever. We're now in a position where we may learn that daily use of tenofovir gel is equally safe and could possibly be even more effective than the regimen tested in CAPRISA 004," commented MTN Co-Principal Investigator Ian McGowan, M.D., Ph.D., FRCP, professor of medicine in the division of gastroenterology, hepatology and nutrition with a joint appointment in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine.

"It is gratifying that we are a step closer to identifying a safe and effective HIV prevention method for women. But to know for certain that tenofovir gel is effective, additional studies must be performed, because we can't be sure that what worked for the women in CAPRISA 004 will be the same for women elsewhere," said Mike Chirenje, M.D., FRCOG, associate professor and consultant gynecologist in the department of obstetrics and gynecology at the University of Zimbabwe in Harare and co-chair of the VOICE Study. "VOICE hopes to answer some of the questions about tenofovir gel ¡V and oral PrEP ¡V that CAPRISA 004 was not designed to address."

"Both studies are about finding safe, effective choices for women, whether that choice is a gel used with sex or a gel or tablet used every day," added Jeanne Marrazzo, M.D., M.P.H., VOICE Study co-chair, and professor of medicine in the division of allergy and infectious diseases at the University of Washington in Seattle.

"Some women may prefer to use a product only when they have sex; others may prefer ¡V or require ¡V protection more often. CAPRISA 004 and VOICE are complementary studies that together can give us a substantial amount of information about these approaches. That's important, because we have to be certain that the evidence base for any approach is rock solid before that intervention should be made available more broadly to women at risk for HIV."

VOICE is funded by the by the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases with co-funding from the National Institute of Mental Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, all components of the U.S. National Institutes of Health (NIH).

Women represent nearly 60 percent of adults living with HIV in sub-Saharan Africa, and in several southern African countries young women are at least three times more likely to be HIV-positive than young men. In most cases, women acquire HIV through sexual intercourse with an infected male partner.

Although correct and consistent use of male condoms has been shown to prevent HIV infection, women often cannot control if or when condoms are used by their male partners. Moreover, women are twice as likely as their male partners to acquire HIV during unprotected sex, due in part to biological factors that make them more susceptible to infection.

Lisa Rossi | EurekAlert!
Further information:
http://www.upmc.edu

Further reports about: Aids CAPRISA HIV HIV infection MTN Microbicide Voice health services infectious disease

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Fraunhofer ISE Pushes World Record for Multicrystalline Silicon Solar Cells to 22.3 Percent

25.09.2017 | Power and Electrical Engineering

Usher syndrome: Gene therapy restores hearing and balance

25.09.2017 | Health and Medicine

An international team of physicists a coherent amplification effect in laser excited dielectrics

25.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>